Flood v. Wyeth Laboratories, Inc.

183 Cal. App. 3d 1272, 228 Cal. Rptr. 700, 57 A.L.R. 4th 901, 1986 Cal. App. LEXIS 1877
CourtCalifornia Court of Appeal
DecidedJuly 31, 1986
DocketB007332
StatusPublished
Cited by8 cases

This text of 183 Cal. App. 3d 1272 (Flood v. Wyeth Laboratories, Inc.) is published on Counsel Stack Legal Research, covering California Court of Appeal primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Flood v. Wyeth Laboratories, Inc., 183 Cal. App. 3d 1272, 228 Cal. Rptr. 700, 57 A.L.R. 4th 901, 1986 Cal. App. LEXIS 1877 (Cal. Ct. App. 1986).

Opinion

Opinion

ASHBY, J.

Minor appellant Melissa Flood 1 appeals from a dismissal following a judgment upon the pleadings in favor of respondent Wyeth Laboratories, Inc. (Wyeth). Appellant received a combined diphtheria, pertussis (whooping cough) and tetanus (DPT) immunization, which allegedly caused her severe brain damage. Wyeth was the manufacturer of the vaccine. She sued Wyeth for negligence and strict products liability. The trial court *1275 found Wyeth immune from liability pursuant to Health & Safety Code section 429.36. While cognizant of the liability problem caused by vaccines which cannot be made safe and the growing insurance costs borne by the vaccine manufacturers, we find that neither the section interpreted by the trial court nor the statutory scheme that requires immunization for school-age children (Health & Saf. Code, §§ 3380-3390) extends a grant of immunity to the manufacturer of the vaccine, and reverse the trial court’s judgment.

I

Wyeth presents us with a compelling argument: Every child in this state must receive the DPT vaccine before being admitted into a school of any kind. (Health & Saf. Code, §§ 3380-3390.) 2 The DPT vaccine is not completely safe. If manufacturers are not granted immunity and are forced to defend against inevitable lawsuits, they will cease manufacturing and the vaccine will become unavailable. The legislative purpose in requiring the vaccine—total elimination of diphtheria, pertussis, and tetanus—will be thwarted. Therefore, Wyeth contends, by the act of requiring DPT vaccination the Legislature must have granted immunity to DPT vaccine manufacturers to prevent the law from becoming impossible to implement.

The Legislature of this state, and lawmakers in general, are faced with a serious dilemma where the population is threatened by infectious deadly disease and the immunization against the disease also presents some risks. The Legislature must decide whether the risks inherent in the disease outweigh the risks present in the vaccine. When that question is resolved in favor of the vaccine, the result is mass inoculation. How does the Legislature assure a vaccine supply? Wyeth suggests this is accomplished only through immunizing the manufacturers from liability. There is the possibility, however, that the Legislature intended that the market place would assure a DPT vaccine supply. Since every child in California must receive the vaccine, the demand is large and ongoing. There appear to be no price controls. If a manufacturer finds costs rising due to lawsuits or insurance premium hikes, the manufacturer is free to raise the price of the vaccine.

The legislative history of section 3380 et seq., unfortunately, makes no mention of the Legislature’s thinking with respect to vaccine supply. The absence of any discussion, however, supports our analysis. There is nothing *1276 in the statutes requiring immunization against communicable childhood diseases which can be read to require immunity for manufacturers to assure an adequate vaccine supply, and there is nothing in their statutory history that can be so read.

We have been referred by Wyeth to the National Swine Flu Immunization Program (former 42 U.S.C. § 247b, as found in Historical Note following current section). The swine flu legislation specifically provided immunity for the manufacturers, which will be discussed in more detail in section II of this opinion. What is of import to us here is that the immunity was granted before the swine flu vaccine was developed. The immunity was an incentive given by Congress to the manufacturers to prevent what was seen as an impending national emergency. 3 (Wolfe v. Merrill Nat. Laboratories, Inc. (D.C.Tenn. 1977) 433 F.Supp. 231, 234. See Kearl v. Lederle Laboratories (1985) 172 Cal.App.3d 812, 824 [218 Cal.Rptr. 453].) As Wyeth states in its brief, the DPT vaccine was available well before the enactment of the Health and Safety Code sections which require immunization for the school-age children of this state. This distinction is another reason why we decline to follow Wyeth’s contention that the policy of mandatory immunization necessarily includes an immunity from liability for the manufacturers of the vaccine.

Wyeth is in error in arguing that a finding of its liability by a court or a jury is a finding that the Legislature should not have made the vaccination mandatory or have allowed the Wyeth vaccine to be used in the mandatory program. A suit against Wyeth for negligence or even strict liability is not an attack on the police power of the legislative branch. Analogous suits have been brought in this state. Section 3380 et seq. also requires immunization against poliomyelitis. Manufacturers of the poliomyelitis vaccine have been sued. (See Kearl v. Lederle Laboratories, supra, 172 Cal.App.3d 812; Grinnell v. Charles Pfizer & Co. (1969) 274 Cal.App.2d 424 [79 Cal.Rptr. 369].) Kearl in particular counters the contention that the legislation requiring vaccination against childhood diseases precludes the finding of any liability by a vaccine manufacturer. The court in Kearl held that manufacturers of vaccines are subject to liability under a strict products liability design defect theory, unless the trial court makes certain evidentiary findings 4 (172 Cal.App.3d at pp. 829-831); under a theory of strict products *1277 liability for manufacturing defects (id., at p. 831); and for negligent warning defects (id., at pp. 833-834).

The statutes requiring vaccination do not compel a finding that the manufacturers are immune from suit. Wyeth is not alone in predicting that a DPT vaccine shortage will be caused by the suits brought against the manufacturers, because production will become unprofitable. (See Horn, Vaccine Crisis Spurs Bills in Congress (Summer 1985) 10 Litigation News 5.) If this should occur, we would expect the Legislature to intervene to prevent the resulting health crisis. This is a legislative function. We are bound by the principles of legislative interpretation, the most fundamental rule of which is that “the court should ascertain the intent of the Legislature so as to effectuate the purpose of the law.” (Select Base Materials v. Board of Equal. (1959) 51 Cal.2d 640, 645 [335 P.2d 672]; California Teachers Assn. v. San Diego Community College Dist. (1981) 28 Cal.3d 692, 698 [170 Cal.Rptr. 817, 621 P.2d 856]; Moyer v. Workmen’s Comp. Appeals Bd. (1973) 10 Cal.3d 222, 230 [110 Cal.Rptr. 144,

Related

Kirby v. County of Fresno
242 Cal. App. 4th 940 (California Court of Appeal, 2015)
Salasguevara v. Frye
31 Cal. App. 4th 330 (California Court of Appeal, 1995)
Savina v. Sterling Drug, Inc.
795 P.2d 915 (Supreme Court of Kansas, 1990)
Shackil v. Lederle Laboratories
530 A.2d 1287 (New Jersey Superior Court App Division, 1987)
Toner v. Lederle Laboratories
732 P.2d 297 (Idaho Supreme Court, 1987)
Untitled California Attorney General Opinion
California Attorney General Reports, 1987

Cite This Page — Counsel Stack

Bluebook (online)
183 Cal. App. 3d 1272, 228 Cal. Rptr. 700, 57 A.L.R. 4th 901, 1986 Cal. App. LEXIS 1877, Counsel Stack Legal Research, https://law.counselstack.com/opinion/flood-v-wyeth-laboratories-inc-calctapp-1986.